- Q1 2024 Bolt Biotherapeutics Inc Earnings Call TranscriptMay 14, 2024$1.32 (-0.75%)Earnings
- Bolt Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Bolt Biotherapeutics Inc at Cowen Health Care Conference TranscriptMar 07, 2023
- Bolt Biotherapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 16, 2023
- Bolt Biotherapeutics Inc at Guggenheim Healthcare Talks Oncology Day TranscriptFeb 08, 2023
- Bolt Biotherapeutics Inc at Stifel Healthcare Conference TranscriptNov 16, 2022
- Bolt Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2022
- Bolt Biotherapeutics Inc at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Bolt Biotherapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 09, 2022
- Bolt Biotherapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Bolt Biotherapeutics Inc CMC Considerations For In-Human Studies with Drs. Edith Perez And Nathan Ihle TranscriptSep 23, 2020
Bolt Biotherapeutics Inc at Cowen Health Care Conference Transcript
Fantastic. Thanks, everybody, for joining. The next company to present is Bolt Biotherapeutics. And it's my pleasure to introduce Randall Schatzman, the CEO of Bolt. Thanks, Randall.
Thank you, Boris. Thanks for the kind introduction. It's a pleasure to be here today. And thanks to the team at TD Cowen for inviting us to participate in the conference. We've had a great schedule so far.
So I wanted to acknowledge a couple of my colleagues who are joining me today. Willie Quinn, who's Bolt's Chief Financial Officer; and Edith Perez, who's Bolt's Chief Medical Officer. And all of us will be available to answer your questions after my opening remarks here. So we will be making some forward-looking statements today, and I encourage listeners to refer to our filings with the SEC to understand the risks of our business along the way.
And Bolt, we're pursuing a strategy of novel immuno-oncology therapeutics that are targeted and allow us to access both the innate and the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)